United Therapeutics Revenue by Segment

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Tyvaso	1.83B	1.79B	1.71B	1.62B	1.56B	1.45B	1.37B	1.23B
Tyvaso Growth	17.66%	23.39%	25.33%	31.34%	38.18%	36.87%	45.60%	41.32%
Remodulin	533.30M	535.70M	548.30M	538.10M	518.70M	521.50M	501.40M	494.80M
Remodulin Growth	2.81%	2.72%	9.35%	8.75%	3.29%	7.50%	2.35%	-1.08%
Orenitram	483.50M	465.60M	448.80M	434.30M	410.60M	389.40M	377.40M	359.40M
Orenitram Growth	17.75%	19.57%	18.92%	20.84%	16.95%	12.35%	14.19%	10.55%
Unituxin	232.00M	245.20M	238.50M	238.70M	225.40M	215.60M	208.20M	198.90M
Unituxin Growth	2.93%	13.73%	14.55%	20.01%	24.26%	22.36%	18.03%	8.75%
Adcirca	26.90M	24.20M	23.40M	23.80M	25.90M	26.20M	28.00M	28.90M
Adcirca Growth	3.86%	-7.63%	-16.43%	-17.65%	-20.31%	-27.02%	-27.84%	-30.02%
Other	22.90M	21.50M	20.90M	22.10M	20.50M	16.90M	14.50M	12.10M	-	-	-	-	-	-	-	-	-	-	-	-
Other Growth	11.71%	27.22%	44.14%	82.64%	12.64%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.